SHENGDA BIO-PHARM's major shareholder WanJian Investment plans to reduce its holdings by no more than 3%
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, SHENGDA BIO-PHARM announced that its major shareholder, Tiantai Wanjian Investment Development Center (Limited Partnership) (referred to as "Wanjian Investment"), plans to reduce its holdings of the company's shares by no more than 5.1357 million shares through centralized bidding and block trading within three months after the announcement of this reduction plan, with a proposed reduction ratio not exceeding 3% of the company's total share capital
According to the announcement from Zhitong Finance APP, SHENGDA BIO-PHARM (603079.SH) stated that its major shareholder, Tiantai Wanjian Investment Development Center (Limited Partnership) (referred to as "Wanjian Investment"), plans to reduce its holdings of the company's shares by no more than 5.1357 million shares within three months after the announcement of this reduction plan, through centralized bidding and block trading, with a proposed reduction ratio not exceeding 3% of the company's total share capital